Journal
CANCER TREATMENT REVIEWS
Volume 38, Issue 6, Pages 626-640Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2011.11.003
Keywords
Non-small cell lung cancer; Targeted agents; Chemoradiotherapy; EGFR inhibitors; Antiangiogenic agents; Phase I trials; Preclinical models; Radiotherapy; Combined modality treatment
Categories
Funding
- Cancer Research UK
- AstraZeneca
- AstraZeneca (MEKRT) [NCT01146756]
Ask authors/readers for more resources
In recent years there has been undoubted progress in the evaluation and development of targeted agents for non-small cell lung cancer (NSCLC). A major contributor has been the discovery of molecular subtypes harbouring a critical oncogenic driver mutation, specifically sensitizing mutations in the epidermal growth factor receptor (EGFR) gene and the EML4-ALK gene translocation. Radiotherapy is a cornerstone of therapy for the curative intent treatment of early stage, localized disease; and for the palliation of symptoms in advanced, metastatic disease. In this molecular targeted era there is limited understanding of how best to combine targeted agents with radiotherapy and in general clinical studies with radiotherapy have lagged behind studies of targeted agents with chemotherapy. Here we summarise the progress made to date and highlight future directions. (C) 2011 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available